Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from AstraZeneca ( (GB:AZN) ) is now available.
AstraZeneca has secured U.S. FDA approval for a new subcutaneous, once-weekly autoinjector formulation of its lupus drug Saphnelo, branded as the Saphnelo Pen, enabling adult patients with systemic lupus erythematosus to self-administer treatment at home on top of standard therapy. The decision is backed by Phase III TULIP-SC data showing clinically meaningful reductions in disease activity with a safety profile consistent with the existing IV formulation, positioning AstraZeneca to broaden Saphnelo’s reach, enhance patient convenience and potentially strengthen its competitive standing in autoimmune diseases while generating additional royalty-bearing U.S. revenue for Bristol-Myers Squibb under a long-standing licensing agreement.
The most recent analyst rating on (GB:AZN) stock is a Buy with a £160.00 price target. To see the full list of analyst forecasts on AstraZeneca stock, see the GB:AZN Stock Forecast page.
Spark’s Take on AZN Stock
According to Spark, TipRanks’ AI Analyst, AZN is a Outperform.
The score is driven primarily by strong underlying financial performance and a constructive earnings outlook (growth guidance and pipeline progress). This is tempered by valuation (P/E ~30), recent free-cash-flow variability, and technical signals that appear overextended despite the broader uptrend.
To see Spark’s full report on AZN stock, click here.
More about AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company focused on the discovery, development and commercialisation of prescription medicines across Oncology, Rare Diseases and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Headquartered in Cambridge, U.K., the company has a 50-year heritage in respiratory care and a growing portfolio of biologics and new modalities targeting immune‑mediated diseases, with products sold in more than 125 countries.
Average Trading Volume: 2,671,451
Technical Sentiment Signal: Buy
Current Market Cap: £216.4B
Find detailed analytics on AZN stock on TipRanks’ Stock Analysis page.